Understand how semaglutide shows strong benefits in MASH treatment, improving liver health and reducing weight.

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

For patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, semaglutide is associated with improved liver histologic outcomes.

Financial report for the period 1 January 2025 to 31 March 2025 Operating profit increased by 22% in Danish kroner and by 20% ...

Ozempic, a diabetes drug, shows promise for liver disease. Research indicates it can reverse non-alcoholic steatohepatitis. A ...

The reserarchers found that a weekly dose of semaglutide was effective at treating Metabolic Dysfunction-Associated ...

Results from studies at Virginia Commonwealth University (VCU) show that an Aramchol and Bayer's Regorafenib drug combination significantly reduced hepatic tumor ...

Data across obesity, cardiovascular disease, MASH, type 2 diabetes, as well as advances in obesity-related care to be ...

The international study led by a Virginia Commonwealth University researcher found the medication semaglutide, commonly known ...

A major international study has found that semaglutide, a drug already used to treat type 2 diabetes and obesity, can ...

Semaglutide, the blockbuster drug better known by brand names like Ozempic and Wegovy, has now shown significant promise in ...

Wegovy (semaglutide) could offer a new option to treat severe liver disease based on new clinical trial evidence. The GLP-1 ...